More articles from From the editor
- When a quick sound bite won’t do
In the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, why did more patients die if they got intensive therapy than if they got standard therapy? In this issue of the Journal, an investigator in this trial gives his analysis.
- And then there were none? An internist’s reflections
In this issue, Dr. Thomas Lansdale eloquently expresses a common theme: medicine just isn’t that much fun anymore. We’d like to hear some solutions.
- Upgrades to our CME test and to www.ccjm.org
We recently upgraded our Web-based manuscript tracking system, and we are continuing to expand and improve our educational offerings to our readers.
- A drug, a concept, and a clinical trial on trial
The ENHANCE trial, evaluating the addition of a second hypocholesterolemic drug (ezetimibe) to a statin using two surrogate end points in a relatively small number of patients, hit the national news when the two surrogates didn’t match up.
- Meta-analyses, metaphysics, and reality
Be very careful about directly translating conclusions from meta-analyses into clinical practice.
- ‘Blood will have blood’
Why should more patients die when hemoglobin levels are normalized with erythropoiesis-stimulating agents? It could be another case of “messing with Mother Nature.”
- A new series, an old concept, continued value
This month we introduce a new series, The Physical Examination, kicked off by a paper on evaluating pleural effusions. We encourage you to submit your suggestions for topics.
- A report from the department of staph affairs
The evolutionary pressure that we humans are putting on Staphylococcus aureus with our antibiotics is taking this bug to a whole new place.
- Surprisingly nonbenign imaging
Nephrogenic systemic fibrosis is making us revise our view that “MRI with contrast” is a benign test.